Company Annovis Bio, Inc.

Equities

ANVS

US03615A1088

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nyse Other stock markets 04:00:02 2024-04-24 pm EDT			5-day change	1st Jan Change
12.74 ^USD	+7.24%		+41.71%	-31.87%

Apr. 01	Annovis Announces Publication That Supports Understanding of Buntanetap?s Mechanism of Action in Humans	CI
Mar. 29	Annovis Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Annovis Bio, Inc. is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimerâs disease (AD), Parkinsonâs disease (PD) and other chronic neurodegenerative diseases. The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury (TBI) and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from six to three.

Number of employees: 11

Managers	Title	Age	Since
Maria-Luisa Maccecchini FOU	Founder	73	08-04-30
Henry Hagopian DFI	Director of Finance/CFO	56	22-08-28
Melissa Gaines CTO	Chief Tech/Sci/R&D Officer	-	-
Cheng Fang CTO	Chief Tech/Sci/R&D Officer	-	21-05-17
Andrew Walsh PRN	Corporate Officer/Principal	-	Nov. 30
Eve M. Damiano LAW	General Counsel	-	21-12-31

Members of the board	Title	Age	Since
Michael Hoffman CHM	Chairman	73	13-12-31
Maria-Luisa Maccecchini FOU	Founder	73	08-04-30
Reid McCarthy BRD	Director/Board Member	70	21-04-08
Claudine Bruck BRD	Director/Board Member	69	14-12-31
Mark White BRD	Director/Board Member	68	15-12-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	11,011,299	8,303,262 ( 75.41 %)	0	75.41 %

Name	Equities	%	Valuation
Michael Hoffman 14.89 %	1,639,640	14.89 %	20 M $
Maria-Luisa Maccecchini 9.976 %	1,098,459	9.976 %	13 M $
Vanguard Global Advisers LLC 3.064 %	337,354	3.064 %	4 M $
Adage Capital Partners GP LLC 2.591 %	285,347	2.591 %	3 M $
BlackRock Institutional Trust Co. NA 0.8618 %	94,893	0.8618 %	1 M $
Geode Capital Management LLC 0.6246 %	68,776	0.6246 %	818 434 $
Mark White 0.5555 %	61,167	0.5555 %	727 887 $
Kieger AG 0.4843 %	53,326	0.4843 %	634 579 $
Jeffrey McGroarty 0.4813 %	53,000	0.4813 %	630 700 $
Wescott Financial Advisory Group LLC 0.3779 %	41,607	0.3779 %	495 123 $

Annovis Bio, Inc.

101 Lindenwood Drive Suite 225

19355, Malvern

+484 875 3192

http://www.annovisbio.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.74 USD

Average target price

35.4 USD

Spread / Average Target

+177.86%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
ANNOVIS BIO, INC.	-31.87%	140M
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	104B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.42B
ARGENX SE	+1.51%	22.2B
BIONTECH SE	-16.53%	21.23B
GENMAB A/S	-8.82%	18.33B
WUXI APPTEC CO., LTD.	-42.33%	16.35B
BEIGENE, LTD.	-20.09%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	13.98B
SAREPTA THERAPEUTICS, INC.	+28.85%	11.66B

Bio Therapeutic Drugs